Meeting
2020 Gastrointestinal Cancers Symposium
A single-arm, phase II study of intrahepatic chemotherapy in patients with unresectable colorectal liver metastases.
Authors
Kate Elenna Besel
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Kate Elenna Besel , Yoo-Joung Ko , Paul Jack Karanicolas , Christina Yiyoung Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ON1233
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 162)
Abstract #
162
Poster Bd #
H4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma.
First Author: Jonathan Matthew Hernandez
Poster
2021 Gastrointestinal Cancers Symposium
Implementation of hepatic artery infusion (HAI) chemotherapy for unresectable colorectal liver metastases (CRLM): The University of Miami experience.
First Author: Agustin Pimentel
Poster
2018 ASCO Annual Meeting
Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.
First Author: Marc Ychou
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study.
First Author: Janice Zhao